• Filing Date: 2019-05-14
  • Form Type: 10-Q/A
  • Description: Quarterly report (Amendment)
v3.19.1
C. STOCKHOLDERS EQUITY (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2019
Dec. 31, 2018
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2019
Mar. 31, 2018
Common Stock            
Beginning balance $ 278,435 $ 280,346 $ 132,581 $ 119,031 $ 280,346 $ 119,031
Beginning balance, shares 27,843,327 28,034,487 13,258,051 11,903,133 28,034,487 11,903,133
Sale of common stock     $ 25,011 $ 12,895    
Sale of common stock, shares     2,501,145 1,289,478    
Warrant exercises $ 15,239 $ 2,987        
Warrant exercises, shares 1,523,933 298,682        
401(k) contributions paid in common stock $ 104 $ 123 $ 259 $ 190    
401(k) contributions paid in common stock, shares 10,419 12,279 25,901 18,984    
Stock issued to nonemployees for service $ 774 $ 628 $ 1,241 $ 137    
Stock issued to nonemployees for service, shares 77,449 62,784 124,082 13,705    
Conversion of notes payable and interest to common stock     $ 554      
Conversion of notes payable and interest to common stock, shares     55,373      
Shares issued (returned) for settlement of clinical research costs $ 5,000 $ (5,649) $ 6,600      
Shares issued (returned) for settlement of clinical research costs, shares 500,000 (564,905) 660,000      
Equity based compensation - employees $ (35)          
Equity based compensation - employees, shares (3,500)          
Ending balance $ 299,517 $ 278,435 $ 166,246 $ 132,581 $ 299,517 $ 166,246
Ending balance, shares 29,951,628 27,843,327 16,624,552 13,258,051 29,951,628 16,624,552
Additional Paid-In Capital            
Beginning balance $ 332,775,129 $ 331,312,184 $ 300,975,618 $ 296,298,401 $ 331,312,184 $ 296,298,401
Sale of common stock     4,652,130 2,437,105    
Warrant exercises 2,640,395 646,766        
401(k) contributions paid in common stock 36,779 35,118 36,261 35,690    
Stock issued to nonemployees for service 224,855 201,752 227,254 25,270    
Conversion of notes payable and interest to common stock     108,746      
Shares issued (returned) for settlement of clinical research costs 1,285,000 5,649 1,240,800      
Equity based compensation - employees 530,865 573,660   1,448,098    
Stock issuance cost (43,625)   (94,773)      
Ending balance 337,449,398 332,775,129 307,425,853 300,975,618 337,449,398 307,425,853
Accumulated Deficit            
Beginning balance (330,345,712) (331,591,614) (305,942,239) (299,754,409) (331,591,614) (299,754,409)
Net income (loss) (6,447,681) 1,245,902 (4,708,135) (6,187,830)    
Ending balance (336,793,393) (330,345,712) (310,650,374) (305,942,239) (336,793,393) (310,650,374)
Beginning balance 2,707,852 916 (4,834,040) (3,336,977) 916 (3,336,977)
Sale of common stock     4,667,141 2,450,000    
Warrant exercises 2,655,634 649,753        
401(k) contributions paid in common stock 36,883 35,241 36,520 35,880 72,124 72,400
Stock issued to nonemployees for service 225,629 202,380 228,495 25,407    
Conversion of notes payable and interest to common stock     109,300      
Shares issued (returned) for settlement of clinical research costs 1,290,000 0 1,247,400      
Equity based compensation - employees 530,830 573,660   1,448,098    
Stock issuance cost (43,625)   (94,773)      
Net income (loss) (6,447,681) 1,245,902 (4,708,135) (6,187,830) (5,201,779) (10,895,965)
Ending balance $ 955,522 $ 2,707,852 $ (3,058,275) $ (4,834,040) $ 955,522 $ (3,058,275)